Clinical Trial to Evaluate Safety and Efficacy of a Facial and Lip Moisturizer in Adult Subjects Undergoing a Facial Dermatologic Procedure With Fractional CO2 Laser

Change from baseline of the scores of erythema to 5 ± 1 day for Facial Moisturizer B (Control).

At baseline and at 5 ± 1 day, the study physician will evaluate the corresponding half face and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 5 ± 1 day.

Comparison of erythema scores at5 ± 1 day between TH facial moisturizer and Facial Moisturizer B (Control)

At 5 ± 1 day, the study physician will evaluate both half faces and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 5 ± 1 day scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 5 ± 1 day.

Change from baseline of the scores of erythema to 24 hours for TH facial moisturizer.

At baseline and at 24 hours, the study physician will evaluate the corresponding half face and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 24 hours.

Change from baseline of the scores of erythema to 24 hours for Facial Moisturizer B (Control).

At baseline and at 24 hours, the study physician will evaluate the corresponding half face and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 24 hours.

Comparison of erythema scores at 24 hours between TH facial moisturizer and Facial Moisturizer B (Control)

At 24 hours, the study physician will evaluate both half faces and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 24 hours scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 24 hours.

Change from baseline of the scores of erythema to 1 hour for TH facial moisturizer.

At baseline and at 1 hour, the study physician will evaluate the corresponding half face and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 1 hour.

Change from baseline of the scores of erythema to 1 hour for Facial Moisturizer B (Control).

At baseline and at 1 hour, the study physician will evaluate the corresponding half face and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 1 hour.

Comparison of erythema scores at 1 hour between TH facial moisturizer and Facial Moisturizer B (Control)

At 1 hour, the study physician will evaluate both half faces and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 1-hour scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 1 hour.

Change from baseline of the scores of erythema to 30 minutes for TH facial moisturizer.

At baseline and at 30 minutes, the study physician will evaluate the corresponding half face and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 30 minutes.

Change from baseline of the scores of erythema to 30 minutes for Facial Moisturizer B (Control).

At baseline and at 30 minutes, the study physician will evaluate the corresponding half face and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 30 minutes.

Comparison of erythema scores at 30 minutes between TH facial moisturizer and Facial Moisturizer B (Control)

At 30 minutes, the study physician will evaluate both half faces and score the identified erythemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 30 minutes scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 30 minutes.

Change from baseline of the scores of edema to 21 ± 2 days for TH facial moisturizer.

At baseline and at 21 ± 2 days, the study physician will evaluate the corresponding half face and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 21 ± 2 days.

Change from baseline of the scores of edema to 21 ± 2 days for Facial Moisturizer B (Control).

At baseline and at 21 ± 2 days, the study physician will evaluate the corresponding half face and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 21 ± 2 days.

Comparison of edema scores at 21 ± 2 days between TH facial moisturizer and Facial Moisturizer B (Control)

At 21 ± 2 days, the study physician will evaluate both half faces and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 21 ± 2 day scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 21 ± 2 days.

Change from baseline of the scores of edema to 5 ± 1 day for TH facial moisturizer.

At baseline and at 5 ± 1 day, the study physician will evaluate the corresponding half face and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 5 ± 1 day.

Change from baseline of the scores of edema to 5 ± 1 day for Facial Moisturizer B (Control).

At baseline and at 5 ± 1 day, the study physician will evaluate the corresponding half face and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 5 ± 1 day.

Comparison of edema scores at 5 ± 1 day between TH facial moisturizer and Facial Moisturizer B (Control)

At 5 ± 1 day, the study physician will evaluate both half faces and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 5 ± 1 day scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 5 ± 1 day.

Change from baseline of the scores of edema to 24 hours for TH facial moisturizer.

At baseline and at 24 hours, the study physician will evaluate the corresponding half face and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 24 hours.

Change from baseline of the scores of edema to 24 hours for Facial Moisturizer B (Control).

At baseline and at 24 hours, the study physician will evaluate the corresponding half face and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 24 hours.

Comparison of edema scores at 24 hours between TH facial moisturizer and Facial Moisturizer B (Control)

At 24 hours, the study physician will evaluate both half faces and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 24 hours scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 24 hours.

Change from baseline of the scores of edema to 1 hour for TH facial moisturizer.

At baseline and at 1 hour, the study physician will evaluate the corresponding half face and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 1 hour.

Change from baseline of the scores of edema to 1 hour for Facial Moisturizer B (Control).

At baseline and at 1 hour, the study physician will evaluate the corresponding half face and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 1 hour.

Comparison of edema scores at 1 hour between TH facial moisturizer and Facial Moisturizer B (Control)

At 1 hour, the study physician will evaluate both half faces and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 1-hour scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 1 hour.

Change from baseline of the scores of edema to 30 minutes for TH facial moisturizer.

At baseline and at 30 minutes, the study physician will evaluate the corresponding half face and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 30 minutes.

Change from baseline of the scores of edema to 30 minutes for Facial Moisturizer B (Control).

At baseline and at 30 minutes, the study physician will evaluate the corresponding half face and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 30 minutes.

Comparison of edema scores at 30 minutes between TH facial moisturizer and Facial Moisturizer B (Control)

At 30 minutes, the study physician will evaluate both half faces and score the identified edemas according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 30 minutes scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 30 minutes.

Change from baseline of the scores of dryness to 21 ± 2 days for TH facial moisturizer.

At baseline and at 21 ± 2 days, the study physician will evaluate the corresponding half face and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 21 ± 2 days.

Change from baseline of the scores of dryness to 21 ± 2 days for Facial Moisturizer B (Control).

At baseline and at 21 ± 2 days, the study physician will evaluate the corresponding half face and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 21 ± 2 days.

Comparison of dryness scores at 21 ± 2 days between TH facial moisturizer and Facial Moisturizer B (Control)

At 21 ± 2 days, the study physician will evaluate both half faces and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 21 ± 2 day scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 21 ± 2 days.

Change from baseline of the scores of dryness to 5 ± 1 day for TH facial moisturizer.

At baseline and at 5 ± 1 day, the study physician will evaluate the corresponding half face and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 5 ± 1 day.

Change from baseline of the scores of dryness to 5 ± 1 day for Facial Moisturizer B (Control).

At baseline and at 5 ± 1 day, the study physician will evaluate the corresponding half face and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 5 ± 1 day.

Comparison of dryness scores at 5 ± 1 day between TH facial moisturizer and Facial Moisturizer B (Control)

At 5 ± 1 day, the study physician will evaluate both half faces and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 5 ± 1 day scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 5 ± 1 day.

Change from baseline of the scores of dryness to 24 hours for TH facial moisturizer.

At baseline and at 24 hours, the study physician will evaluate the corresponding half face and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 24 hours.

Change from baseline of the scores of dryness to 24 hours for Facial Moisturizer B (Control).

At baseline and at 24 hours, the study physician will evaluate the corresponding half face and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 24 hours.

Comparison of dryness scores at 24 hours between TH facial moisturizer and Facial Moisturizer B (Control)

At 24 hours, the study physician will evaluate both half faces and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 24 hours scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 24 hours.

Change from baseline of the scores of dryness to 1 hour for TH facial moisturizer.

At baseline and at 1 hour, the study physician will evaluate the corresponding half face and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 1 hour.

Change from baseline of the scores of dryness to 1 hour for Facial Moisturizer B (Control).

At baseline and at 1 hour, the study physician will evaluate the corresponding half face and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 1 hour.

Comparison of dryness scores at 1 hour between TH facial moisturizer and Facial Moisturizer B (Control)

At 1 hour, the study physician will evaluate both half faces and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 1-hour scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 1 hour.

Change from baseline of the scores of dryness to 30 minutes for TH facial moisturizer.

At baseline and at 30 minutes, the study physician will evaluate the corresponding half face and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 30 minutes.

Change from baseline of the scores of dryness to 30 minutes for Facial Moisturizer B (Control).

At baseline and at 30 minutes, the study physician will evaluate the corresponding half face and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 30 minutes.

Comparison of dryness scores at 30 minutes between TH facial moisturizer and Facial Moisturizer B (Control)

At 30 minutes, the study physician will evaluate both half faces and score the identified dryness according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 30 minutes scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 30 minutes.

Change from baseline of the scores of desquamation to 21 ± 2 days for TH facial moisturizer.

At baseline and at 21 ± 2 days, the study physician will evaluate the corresponding half face and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 21 ± 2 days.

Change from baseline of the scores of desquamation to 21 ± 2 days for Facial Moisturizer B (Control).

At baseline and at 21 ± 2 days, the study physician will evaluate the corresponding half face and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 21 ± 2 days.

Comparison of desquamation scores at 21 ± 2 days between TH facial moisturizer and Facial Moisturizer B (Control)

At 21 ± 2 days, the study physician will evaluate both half faces and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 21 ± 2 day scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 21 ± 2 days.

Change from baseline of the scores of desquamation to 5 ± 1 day for TH facial moisturizer.

At baseline and at 5 ± 1 day, the study physician will evaluate the corresponding half face and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 5 ± 1 day.

Change from baseline of the scores of desquamation to 5 ± 1 day for Facial Moisturizer B (Control).

At baseline and at 5 ± 1 day, the study physician will evaluate the corresponding half face and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 5 ± 1 day.

Comparison of desquamation scores at 5 ± 1 day between TH facial moisturizer and Facial Moisturizer B (Control)

At 5 ± 1 day, the study physician will evaluate both half faces and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 5 ± 1 day scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 5 ± 1 day.

Change from baseline of the scores of desquamation to 24 hours for TH facial moisturizer.

At baseline and at 24 hours, the study physician will evaluate the corresponding half face and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 24 hours.

Change from baseline of the scores of desquamation to 24 hours for Facial Moisturizer B (Control).

At baseline and at 24 hours, the study physician will evaluate the corresponding half face and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 24 hours.

Comparison of desquamation scores at 24 hours between TH facial moisturizer and Facial Moisturizer B (Control)

At 24 hours, the study physician will evaluate both half faces and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 24 hours scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 24 hours.

Change from baseline of the scores of desquamation to 1 hour for TH facial moisturizer.

At baseline and at 1 hour, the study physician will evaluate the corresponding half face and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 1 hour.

Change from baseline of the scores of desquamation to 1 hour for Facial Moisturizer B (Control).

At baseline and at 1 hour, the study physician will evaluate the corresponding half face and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 1 hour.

Comparison of desquamation scores at 1 hour between TH facial moisturizer and Facial Moisturizer B (Control)

At 1 hour, the study physician will evaluate both half faces and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 1-hour scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 1 hour.

Change from baseline of the scores of desquamation to 30 minutes for TH facial moisturizer.

At baseline and at 30 minutes, the study physician will evaluate the corresponding half face and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 30 minutes.

Change from baseline of the scores of desquamation to 30 minutes for Facial Moisturizer B (Control).

At baseline and at 30 minutes, the study physician will evaluate the corresponding half face and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 30 minutes.

Comparison of desquamation scores at 30 minutes between TH facial moisturizer and Facial Moisturizer B (Control)

At 30 minutes, the study physician will evaluate both half faces and score the identified desquamations according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 30 minutes scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 30 minutes.

Change from baseline of the scores of stinging to 21 ± 2 days for TH facial moisturizer.

At baseline and at 21 ± 2 days, the study physician will evaluate the corresponding half face and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 21 ± 2 days.

Change from baseline of the scores of stinging to 21 ± 2 days for Facial Moisturizer B (Control).

At baseline and at 21 ± 2 days, the study physician will evaluate the corresponding half face and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 21 ± 2 days.

Comparison of stinging scores at 21 ± 2 days between TH facial moisturizer and Facial Moisturizer B (Control)

At 21 ± 2 days, the study physician will evaluate both half faces and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 21 ± 2 day scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 21 ± 2 days.

Change from baseline of the scores of stinging to 5 ± 1 day for TH facial moisturizer.

At baseline and at 5 ± 1 day, the study physician will evaluate the corresponding half face and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 5 ± 1 day.

Change from baseline of the scores of stinging to 5 ± 1 day for Facial Moisturizer B (Control).

At baseline and at 5 ± 1 day, the study physician will evaluate the corresponding half face and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 5 ± 1 day.

Comparison of stinging scores at 5 ± 1 day between TH facial moisturizer and Facial Moisturizer B (Control)

At 5 ± 1 day, the study physician will evaluate both half faces and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 5 ± 1 day scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 5 ± 1 day.

Change from baseline of the scores of stinging to 24 hours for TH facial moisturizer.

At baseline and at 24 hours, the study physician will evaluate the corresponding half face and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 24 hours.

Change from baseline of the scores of stinging to 24 hours for Facial Moisturizer B (Control).

At baseline and at 24 hours, the study physician will evaluate the corresponding half face and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 24 hours.

Comparison of stinging scores at 24 hours between TH facial moisturizer and Facial Moisturizer B (Control)

At 24 hours, the study physician will evaluate both half faces and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 24 hours scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 24 hours.

Change from baseline of the scores of stinging to 1 hour for TH facial moisturizer.

At baseline and at 1 hour, the study physician will evaluate the corresponding half face and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 1 hour.

Change from baseline of the scores of stinging to 1 hour for Facial Moisturizer B (Control).

At baseline and at 1 hour, the study physician will evaluate the corresponding half face and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 1 hour.

Comparison of stinging scores at 1 hour between TH facial moisturizer and Facial Moisturizer B (Control)

At 1 hour, the study physician will evaluate both half faces and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 1-hour scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 1 hour.

Change from baseline of the scores of stinging to 30 minutes for TH facial moisturizer.

At baseline and at 30 minutes, the study physician will evaluate the corresponding half face and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 30 minutes.

Change from baseline of the scores of stinging to 30 minutes for Facial Moisturizer B (Control).

At baseline and at 30 minutes, the study physician will evaluate the corresponding half face and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 30 minutes.

Comparison of stinging scores at 30 minutes between TH facial moisturizer and Facial Moisturizer B (Control)

At 30 minutes, the study physician will evaluate both half faces and score the identified stingings according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 30 minutes scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 30 minutes.

Change from baseline of the scores of itching to 21 ± 2 days for TH facial moisturizer.

At baseline and at 21 ± 2 days, the study physician will evaluate the corresponding half face and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 21 ± 2 days.

Change from baseline of the scores of itching to 21 ± 2 days for Facial Moisturizer B (Control).

At baseline and at 21 ± 2 days, the study physician will evaluate the corresponding half face and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 21 ± 2 days.

Comparison of itching scores at 21 ± 2 days between TH facial moisturizer and Facial Moisturizer B (Control)

At 21 ± 2 days, the study physician will evaluate both half faces and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 21 ± 2 day scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 21 ± 2 days.

Change from baseline of the scores of itching to 5 ± 1 day for TH facial moisturizer.

At baseline and at 5 ± 1 day, the study physician will evaluate the corresponding half face and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 5 ± 1 day.

Change from baseline of the scores of itching to 5 ± 1 day for Facial Moisturizer B (Control).

At baseline and at 5 ± 1 day, the study physician will evaluate the corresponding half face and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 5 ± 1 day.

Comparison of itching scores at 5 ± 1 day between TH facial moisturizer and Facial Moisturizer B (Control)

At 5 ± 1 day, the study physician will evaluate both half faces and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 5 ± 1 day scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 5 ± 1 day.

Change from baseline of the scores of itching to 24 hours for TH facial moisturizer.

At baseline and at 24 hours, the study physician will evaluate the corresponding half face and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 24 hours.

Change from baseline of the scores of itching to 24 hours for Facial Moisturizer B (Control).

At baseline and at 24 hours, the study physician will evaluate the corresponding half face and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 24 hours.

Comparison of itching scores at 24 hours between TH facial moisturizer and Facial Moisturizer B (Control)

At 24 hours, the study physician will evaluate both half faces and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 24 hours scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 24 hours.

Change from baseline of the scores of itching to 1 hour for TH facial moisturizer.

At baseline and at 1 hour, the study physician will evaluate the corresponding half face and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 1 hour.

Change from baseline of the scores of itching to 1 hour for Facial Moisturizer B (Control).

At baseline and at 1 hour, the study physician will evaluate the corresponding half face and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 1 hour.

Comparison of itching scores at 1 hour between TH facial moisturizer and Facial Moisturizer B (Control)

At 1 hour, the study physician will evaluate both half faces and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 1-hour scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 1 hour.

Change from baseline of the scores of itching to 30 minutes for TH facial moisturizer.

At baseline and at 30 minutes, the study physician will evaluate the corresponding half face and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the TH Facial moisturizer.

Time frame: 30 minutes.

Change from baseline of the scores of itching to 30 minutes for Facial Moisturizer B (Control).

At baseline and at 30 minutes, the study physician will evaluate the corresponding half face and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on the corresponding half face. The change from baseline will be evaluated to assess the clinical efficacy of the Facial Moisturizer B (Control).

Time frame: 30 minutes.

Comparison of itching scores at 30 minutes between TH facial moisturizer and Facial Moisturizer B (Control)

At 30 minutes, the study physician will evaluate both half faces and score the identified itching according to the following intensity scale: 0 (absent); 1 (mild); 2 (moderate); 3 (intense). This scale will be used to classify the clinical evaluation on each half face. The 30 minutes scores of each half face will be compared with each other to compare the clinical efficacy of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 30 minutes.

Self-Perceived Efficacy Questionnaire at 30 minutes

Perceived efficacy related to the product usage will be subjectively evaluated by the participants through a questionnaire with questions related to use of the TH facial moisturizer and TH lip moisturezer produts. Participants will answer each question using a qualitative scale (agreement scale). This questionnaire will be used to evaluate the efficacy of TH Facial Moisturizing and TH Lip Moisturizer regarding skin regeneration after dermatological facial procedure with CO2 fractional laser in adult participants. The responses for each question will be provided as percentages.

Time frame: 30 minutes

Self-Perceived Efficacy Questionnaire at 24 hours

Perceived efficacy related to the product usage will be subjectively evaluated by the participants through a questionnaire with questions related to use of the TH facial moisturizer and TH lip moisturezer produts. Participants will answer each question using a qualitative scale (agreement scale). This questionnaire will be used to evaluate the efficacy of TH Facial Moisturizing and TH Lip Moisturizer regarding skin regeneration after dermatological facial procedure with CO2 fractional laser in adult participants. The responses for each question will be provided as percentages.

Time frame: 24 hours

Self-Perceived Efficacy Questionnaire at 5 ± 1 day

Perceived efficacy related to the product usage will be subjectively evaluated by the participants through a questionnaire with questions related to use of the TH facial moisturizer and TH lip moisturezer produts. Participants will answer each question using a qualitative scale (agreement scale). This questionnaire will be used to evaluate the efficacy of TH Facial Moisturizing and TH Lip Moisturizer regarding skin regeneration after dermatological facial procedure with CO2 fractional laser in adult participants. The responses for each question will be provided as percentages.

Time frame: 5 ± 1 day

Self-Perceived Efficacy Questionnaire at 21 ± 2 days

Perceived efficacy related to the product usage will be subjectively evaluated by the participants through a questionnaire with questions related to use of the TH facial moisturizer and TH lip moisturizer products. Participants will answer each question using a qualitative scale (agreement scale). This questionnaire will be used to evaluate the efficacy of TH Facial Moisturizing and TH Lip Moisturizer regarding skin regeneration after dermatological facial procedure with CO2 fractional laser in adult participants. The responses for each question will be provided as percentages.

Time frame: 21 ± 2 days

Visual skin condition of the whole face at baseline captured photographically

Face images will be captured using a recognized device (Visia CR) at baseline to visualize the skin condition of these areas after the dermatological facial procedure with CO2 fractional laser and before the TH Facial moisturizer and Facial Moisturizer B (Control) usage on each determined half face. No analysis is planned. These images will be used as a qualitative complement to the other results for TH Facial moisturizer.

Time frame: baseline

Visual skin condition of the whole face at 1 hour captured photographically

Face images will be captured using a recognized device (Visia CR) at 1 hour to visualize the skin condition of these areas after the TH Facial moisturizer and Facial Moisturizer B (Control) supervised application on each determined half face. No analysis is planned. These images will be used as a qualitative complement to the other results for TH Facial moisturizer.

Time frame: 1 hour

Visual skin condition of the whole face at 24 hours captured photographically

Face images will be captured using a recognized device (Visia CR) at 24 hours to visualize the skin condition of these areas after the TH Facial moisturizer and Facial Moisturizer B (Control) usage on each determined half face. No analysis is planned. These images will be used as a qualitative complement to the other results for TH Facial moisturizer.

Time frame: 24 hours

Visual skin condition of the whole face at 5 ± 1 day captured photographically

Face images will be captured using a recognized device (Visia CR) at 5 ± 1 day to visualize the skin condition of these areas after the TH Facial moisturizer and Facial Moisturizer B (Control) usage on each determined half face. No analysis is planned. These images will be used as a qualitative complement to the other results for TH Facial moisturizer.

Time frame: 5 ± 1 day

Visual skin condition of the whole face at 21 ± 2 days captured photographically

Face images will be captured using a recognized device (Visia CR) at 21 ± 2 days to visualize the skin condition of these areas after the TH Facial moisturizer and Facial Moisturizer B (Control) usage on each determined half face. No analysis is planned. These images will be used as a qualitative complement to the other results for TH Facial moisturizer.

Time frame: 21 ± 2 days

Mean change from baseline to 21 ± 2 days in skin hydration level for TH facial moisturizer.

Skin hydration level of the determined half face will be measured with corneometer, a recognized device that determine the water content of stratum corneum. This measure will be used to determine the effect of the TH facial moisturizer on skin hydration of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 21 ± 2 days of usage.

Time frame: 21 ± 2 days

Mean change from baseline to 21 ± 2 days in skin hydration level for Facial Moisturizer B (Control).

Skin hydration level of the determined half face will be measured with corneometer, a recognized device that determine the water content of stratum corneum. This measure will be used to determine the effect of the Facial Moisturizer B (Control) on skin hydration of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 21 ± 2 days of usage.

Time frame: 21 ± 2 days

Comparison of skin hydration level at 21 ± 2 days between TH facial moisturizer and Facial Moisturizer B (Control)

At 21 ± 2 days, skin hydration level of both half faces will be measured with corneometer, a recognized device that determine the water content of stratum corneum. This measure will be used to determine the effect of both products on skin hydration of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 21 ± 2 days of usage. The 21 ± 2 days measures of each half face will be compared with each other to compare the skin hydration of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 21 ± 2 days.

Mean change from baseline to 24 hours in skin hydration level for TH facial moisturizer.

Skin hydration level of the determined half face will be measured with corneometer, a recognized device that determine the water content of stratum corneum. This measure will be used to determine the effect of the TH facial moisturizer on skin hydration of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 24 hours of usage.

Time frame: 24 hours

Mean change from baseline to 24 hours in skin hydration level for Facial Moisturizer B (Control).

Skin hydration level of the determined half face will be measured with corneometer, a recognized device that determine the water content of stratum corneum. This measure will be used to determine the effect of the Facial Moisturizer B (Control) on skin hydration of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 24 hours of usage.

Time frame: 24 hours

Comparison of skin hydration level at 24 hours between TH facial moisturizer and Facial Moisturizer B (Control)

At 24 hours, skin hydration level of both half faces will be measured with corneometer, a recognized device that determine the water content of stratum corneum. This measure will be used to determine the effect of both products on skin hydration of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 24 hours of usage. The 24 hours measures of each half face will be compared with each other to compare the skin hydration of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 24 hours.

Mean change from baseline to 1 hour in skin hydration level for TH facial moisturizer.

Skin hydration level of the determined half face will be measured with corneometer, a recognized device that determine the water content of stratum corneum. This measure will be used to determine the effect of the TH facial moisturizer on skin hydration of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 1 hour of supervised application.

Time frame: 1 hour

Mean change from baseline to 1 hour in skin hydration level for Facial Moisturizer B (Control).

Skin hydration level of the determined half face will be measured with corneometer, a recognized device that determine the water content of stratum corneum. This measure will be used to determine the effect of the Facial Moisturizer B (Control) on skin hydration of the study population who underwent the dermatological facial procedure with CO2 fractional laser 1 hour of supervised application.

Time frame: 1 hour

Comparison of skin hydration level at 1 hour between TH facial moisturizer and Facial Moisturizer B (Control)

At 1 hour, skin hydration level of both half faces will be measured with corneometer, a recognized device that determine the water content of stratum corneum. This measure will be used to determine the effect of both products on skin hydration of the study population who underwent the dermatological facial procedure with CO2 fractional laser 1 hour of supervised application. The 1-hour measures of each half face will be compared with each other to compare the skin hydration of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 1 hour

Mean change from baseline to 21 ± 2 days in transepidermal water loss (TEWL) to assess skin barrier integrity for TH facial moisturizer.

Skin barrier integrity of the determined half face will be measured with Tewameter, a recognized device that determine the transepidermal water loss. Lower levels of TEWL may be related to a more integrate skin barrier. This measure will be used to determine the effect of the TH facial moisturizer on skin barrier integrity of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 21 ± 2 days of usage.

Time frame: 21 ± 2 days

Mean change from baseline to 21 ± 2 days in transepidermal water loss (TEWL) to assess skin barrier integrity for Facial Moisturizer B (Control).

Skin barrier integrity of the determined half face will be measured with Tewameter, a recognized device that determine the transepidermal water loss. Lower levels of TEWL may be related to a more integrate skin barrier. This measure will be used to determine the effect of the Facial Moisturizer B (Control) on skin barrier integrity of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 21 ± 2 days of usage.

Time frame: 21 ± 2 days

Comparison of transepidermal water loss (TEWL) to assess skin barrier integrity at 21 ± 2 days between TH facial moisturizer and Facial Moisturizer B (Control)

At 21 ± 2 days, the transepidermal water loss of both half faces will be measured with Tewameter, a recognized device that determine the transepidermal water loss. Lower levels of TEWL may be related to a more integrate skin barrier. This measure will be used to determine the effect of both products on skin barrier integrity of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 21 ± 2 days of usage. The 21 ± 2 days measures of each half face will be compared with each other to compare the skin barrier integrity of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 21 ± 2 days.

Mean change from baseline to 24 hours in transepidermal water loss (TEWL) to assess skin barrier integrity for TH facial moisturizer.

This measure will be used to determine the effect of the TH facial moisturizer on skin barrier integrity of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 24 hours of usage. Skin barrier integrity of the determined half face will be measured with Tewameter, a recognized device that determine the transepidermal water loss. Lower levels of TEWL may be related to a more integrate skin barrier.

Time frame: 24 hours

Mean change from baseline to 24 hours in transepidermal water loss (TEWL) to assess skin barrier integrity for Facial Moisturizer B (Control).

This measure will be used to determine the effect of the Facial Moisturizer B (Control) on skin barrier integrity of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 24 hours of usage. Skin barrier integrity of the determined half face will be measured with Tewameter, a recognized device that determine the transepidermal water loss. Lower levels of TEWL may be related to a more integrate skin barrier.

Time frame: 24 hours

Comparison of transepidermal water loss (TEWL) to assess skin barrier integrity at 24 hours between TH facial moisturizer and Facial Moisturizer B (Control)

At 24 hours, the transepidermal water loss of both half faces will be measured with Tewameter, a recognized device that determine the transepidermal water loss. Lower levels of TEWL may be related to a more integrate skin barrier. This measure will be used to determine the effect of both products on skin barrier integrity of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 24 hours of usage. The 24 hours measures of each half face will be compared with each other to compare the skin barrier integrity of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 24 hours.

Mean change from baseline to 1 hour in transepidermal water loss (TEWL) to assess skin barrier integrity for TH facial moisturizer.

This measure will be used to determine the effect of the TH facial moisturizer on skin barrier integrity of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 1 hour of supervised application. Skin barrier integrity of the determined half face will be measured with Tewameter, a recognized device that determine the transepidermal water loss. Lower levels of TEWL may be related to a more integrate skin barrier.

Time frame: 1 hour

Mean change from baseline to 1 hour in transepidermal water loss (TEWL) to assess skin barrier integrity for Facial Moisturizer B (Control).

This measure will be used to determine the effect of the Facial Moisturizer B (Control) on skin barrier integrity of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 1 hour of supervised application. Skin barrier integrity of the determined half face will be measured with Tewameter, a recognized device that determine the transepidermal water loss. Lower levels of TEWL may be related to a more integrate skin barrier.

Time frame: 1 hour

Comparison of transepidermal water loss (TEWL) to assess skin barrier integrity at 1 hour between TH facial moisturizer and Facial Moisturizer B (Control)

At 1 hour, the transepidermal water loss of both half faces will be measured with Tewameter, a recognized device that determine the transepidermal water loss. Lower levels of TEWL may be related to a more integrate skin barrier. This measure will be used to determine the effect of both products on skin barrier integrity of the study population who underwent the dermatological facial procedure with CO2 fractional laser after 1 hour of supervised application. The 1-hour measures of each half face will be compared with each other to compare the skin barrier integrity of one product with the other (TH facial moisturizer versus Facial Moisturizer B (Control)).

Time frame: At 1 hour.